SecBot SecBot

AEON

AEON Biopharma, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001837607 Biotech & Drug Discovery
$0.2400 +0.01 (+2.56%)
Oct 23 4:00 PM ET · prev $0.2340
Market cap
$13.8M
Nano cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
🔒 Subscribers only
1 year
−74.5%
from $0.9400 · Oct 24
30 days
−7.7%
from $0.2600
52-week range
$0.1920–1.36
−82% from high · low Aug 21
Avg volume 20D
7.08M
Sep 30 spike 116.17M
Short interest
2.17M
≈4.3% of shares · −26.3%
Days to cover
1.0
at average volume
Insider net
+$243.5K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 2 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/5
Strongest BULLISH AEON Biopharma received official minutes from its FDA BPD Type 2b meeting for ABP-450 (biosimilar to BOTOX)…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $243.5K at an average $0.2117. No open-market sales. Price is 13% above their cost.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better.

  • Short sellersCOVERING

    Short interest −26.3% to 2.17M shares. 1.0 days to cover, ≈4.3% of shares.

  • TrendDOWNTREND

    7% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITIGROUP INCDOUBLED7,315$5.3K
GEODE CAPITAL MANAGEMENT, LLCADD87,062$85.8K
Steward Partners Investment Advisory, LLCDOUBLED1,100$1.1K
GEODE CAPITAL MANAGEMENT, LLCADD60,134$66.1K
UBS Group AGDOUBLED4,052$4.5K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED47,073$38.1K
UBS Group AGNEAR_EXIT1,192$964.00
UBS Group AGDOUBLED31,600$24.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 1, 2026Lake Street
MAINTAIN
MAINTAINBuy
Aug 14, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 30, 2026Lake Street
INITIATE
INITIATEBuy

Insider ledger

Form 4
$243.5K
bought · 1 insider
$0
sold · 0 insiders
+13.4%
vs their $0.2117 cost
DateInsiderTypeValue
Aug 19, 2026
LYNCH TIMOTHY P
10%+ Owner
BUY$243.5K
Jun 17, 2026
Thunen Shelley B
Director
AWARD222,684 sh
Jun 17, 2026
Carter Eric G
Director
AWARD222,684 sh
Jun 17, 2026
FISCHER JOST
Director
AWARD222,684 sh
Jun 17, 2026
Forth Marc
Director
AWARD222,684 sh
Jun 17, 2026
PALMISANO ROBERT J
Director
AWARD222,684 sh
Apr 2, 2026
Bencich John
CHIEF FINANCIAL OFFICER
AWARD754,717 sh
Mar 4, 2026
Sy Jennifer
PRINCIPAL ACCOUNTING OFFICER
AWARD925,925 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
2,171,628
shares short
-26.3%
vs prior settlement
1.0
days to cover
≈4.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
AEON Biopharma filed an 8-K furnishing an October 2026 corporate presentation that outlines its strategy to develop…
8-K — Impact 4/10
Sep 30, 2026 SEC
AEON Biopharma received official minutes from its FDA BPD Type 2b meeting for ABP-450 (biosimilar to BOTOX). The FDA…
8-K — Impact 7/10
Sep 30, 2026 Short interest report
Short Interest: AEON down 26% to 2.2M shares
Settlement 2026-09-30 | Days to cover: 1.00 | ≈4.35% of shares outstanding (est.)
Aug 22, 2026 SEC
No summary provided
3 — Impact 5/10
Aug 19, 2026 Press
AEON Biopharma released expanded primary structure and preliminary disulfide bond data for its ABP-450 biosimilar…
Impact 6/10
Aug 19, 2026 Insider
LYNCH TIMOTHY P bought 1,150,000 shares
10%+ Owner @ $0.2117 ($243.5K)
Jun 30, 2026 Inst.
CITIGROUP INC — DOUBLED
7,315 shares ($5.3K)
Jun 17, 2026 Insider
Thunen Shelley B was granted 222,684 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Short interest
Short Interest: AEON down 26% to 2.2M shares
Settlement 2026-09-30 | Days to cover: 1.00 | ≈4.35% of shares outstanding (est.)
Sep 15, 2026
Short interest
Short Interest: AEON up 63% to 2.9M shares
Settlement 2026-09-15 | Days to cover: 1.00 | ≈5.91% of shares outstanding (est.)
Aug 31, 2026
Press release
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical…
Aug 31, 2026
Short interest
Short Interest: AEON up 61% to 1.8M shares
Settlement 2026-08-31 | Days to cover: 1.00 | ≈3.63% of shares outstanding (est.)
Aug 19, 2026
FDA
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with…

SecBot reports

12 filings · 3 press releases · 1 bullish · 6 bearish · 5 neutral
All AEON filing & press-release reports (15)